Amarin Corp Plc (AMRN)

[ziploc_1]

HDG...I agree that, barring an unlikely turn of events...due to exclusivity being lost...success with Vascepa is now dependent on volume.

Success for Amarin means additional indications for Vascepa through investments in patient studies, approvals by regulatory agencies and direct to consumer marketing....These projects require financial assets, which Amarin does not presently have...and is unlikely to have in the near future..Thus the need for Amarin to be sold to a BP.

If not for Amarin's failure to defend its high triglyceride patents, Amarin might have been able to do it alone with its CVD patents in tact, but...due to massive 'skinny label' infringement, those prospects have now evaporated.